U.S. Radiopharmaceuticals Market - Databook 2025 to 2034

The U.S. radiopharmaceuticals market size was evaluated at USD 2.43 billion in 2024 and is expected to grow around USD 5.13 billion by 2034, registering a CAGR of 7.75% from 2025 to 2034.

Highlights of the U.S. Radiopharmaceuticals Market

• By radioisotopes, the technetium-99m segment dominated the U.S. radiopharmaceutical market in 2024.
• By radioisotopes, the gallium-68 segment is anticipated to grow at a noteworthy CAGR during the projected period.
• By application, the cancer segment generated the highest revenue share in 2024.
• By application, the cardiology segment is projected to expand at the fastest CAGR over the projected period.
• By type, the therapeutics segment contributed a higher revenue share in 2024.
• By type, the diagnostic segment is set to experience the fastest rate of market growth from 2025 to 2034.
• By end user, the hospitals and clinics segment registered the highest revenue share in 2024.
• By end user, the medical imaging centers segment is projected to expand rapidly in the market in the coming years.

Industry Valuation and Growth Rate Projection

Radiopharmaceuticals are drugs which contain radioisotopes, widely used in diagnosing tumors and cancers, along with several other medical applications. These isotopes evolve radiation which can be analyzed by imaging equipment outside the body, for instance, PET scanners or gamma cameras. Normally, a few isotopes are coupled with certain molecules to aim for specific tissues, organs, or physiological processes of interest in the individual's body. The U.S. radiopharmaceutical market sees a lot of healthcare professionals utilize radiopharmaceuticals for analyzing imaging in nuclear medical procedures, functional examination, and treatment of different disorders or illnesses by permitting visualization and evaluation of numerous life functions within an organism.

Market Trends

• The U.S. radiopharmaceutical market is boosted by an increasing need for advanced diagnostics, therapies, and precision medicine, mainly in oncology.
• New imaging techniques and radiopharmaceuticals enhance diagnostic accuracy and enable earlier detection of disease.
• Radiopharmaceuticals with aimed delivery mechanisms are gaining supremacy, providing more precise and effective treatment alternatives, mainly in cancer.
• Radiopharmaceuticals are risingly used to diagnose a broader range of conditions, including musculoskeletal and neurological disorders.

Restraints

• Radiopharmaceuticals need specialized manufacturing procedures and equipment, contributing to higher manufacturing costs.
• While effective for detection and treatment, radiopharmaceuticals involve radiation exposure, which can pose challenges to both patients and medical staff.
• Radiopharmaceuticals are theme to strict regulations to ensure effectiveness and safety, which can add to the difficulty of their development and commercialization.

Opportunities

• Cancer is a major contributor to radiopharmaceutical needs, mainly for diagnostic and therapeutic applications in oncology.
• The increasing requirement for radiopharmaceuticals is contributing to opportunities for manufacturing services and contract research, as radiopharmacies provide these services to numerous pharmaceutical firms.
• Radiopharmaceuticals are being determined for applications beyond oncology, like neurology and cardiology, creating thus opportunities for market growth.
• New and enhanced imaging techniques, like PET and SPECT, are increasing the usage of radiopharmaceuticals for analyzing and monitoring numerous diseases.

Recent Developments in the U.S. Radiopharmaceuticals Market

• In April 2025, Novartis received FDA approval, despite challenges posed by U.S. tariffs on pharmaceuticals hamper its progress. With the latest indication additions, radioligand therapy Pluvicto, breast cancer drug Kisqali, and third-generation tyrosine kinase inhibitor Scemblix all delivered double-digit year-across -year sales expansion in the first quarter of 2025.
• In March 2025, Isotopia started Isoprotrace in Germany. DSD Pharma, a trusted pharmaceutical distributor in Germany, will provide as the exclusive partner for the distribution of Isoprotrace via the country, ensuring efficient, consistent delivery to clinics, hospitals, and diagnostic centers across Germany.